Catalyst Dossier · compiled by CeliA 🧫

Teva Pharmaceutical Industries Limited (TEVA)

Pharmaceutical Preparations · market cap $36.7B · as of 2026-06-24

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-07-29

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Teva Pharmaceutical Industries (TEVA) is a large-cap Israeli multinational with 36,830 employees and a ~$38.7B market cap, primarily known as a global generics leader with a meaningful branded and specialty pipeline. The company returned to profitability in 2025 ($1.41B net income on $17.3B revenue) after several years of losses, and carries a complex pipeline spanning neurology, respiratory, oncology, and autoimmune indications. Near-term catalysts include Phase 3 readouts for TEV-56248 (asthma) and a high-impact Phase 3 event flagged for September 2026.

The catalyst path

2026-07-29Earningsimp 5/10
2026-09-15 (est.)Phase 2 · TEV-53408imp 7/10
2026-09-19 (est.)Phase 3 · Fp/ABSimp 9/10
2026-10-31 (est.)Phase 3 · TEV-56248imp 9/10

Pipeline

Asset	Phase	Indication
rasagiline mesylate 1.0 mg	Phase 3	Parkinson's Disease
40 mg glatiramer acetate	Phase 2	Amyotrophic Lateral Sclerosis
Nebulized IVX-0142	Phase 2	Asthma
BDP	Phase 3	Allergic Rhinitis
TEV-56248	Phase 3	Asthma
laquinimod 0.3	Phase 2	Relapsing Remitting Multiple Sclerosis
Tizanidine (sublingual or oral)	Phase 2	Muscle Spasticity
1.0 mg rasagiline mesylate	Phase 3	Parkinson's Disease
Non-Oral Corticosteroid (non-OCS) Asthma Medication	Phase 3	Asthma
BDP HFA	Phase 3	Seasonal Allergic Rhinitis
Budesonide and formoterol fumarate dehydrate (BF) SPIROMAX	Phase 3	Asthma
Beclomethasone Dipropionate 640	Phase 3	Persistent Asthma
TEV-53408	Phase 2	Celiac Disease
CEP-18770	Phase 2	Multiple Myeloma
TV-44749	Phase 3	Schizophrenia
Albuterol Spiromax®	Phase 3	Asthma
TV-1380 150 mg	Phase 2	Cocaine Addiction
desogestrel/ethinyl estradiol and ethinyl estradiol	Phase 2	Hemostasis
Beclomethasone dipropionate HFA Nasal Aerosol	Phase 2	Seasonal Allergic Rhinitis
SD-809	Phase 3	Chorea

Price & technical context

3-month

+14.5%

6-month

+10.5%

12-month

+103.2%

52-wk range

$15.38–$36.34

vs 50-day MA

+1.9%

vs 200-day MA

+17.6%

Realized vol

70.7%

Max drawdown

-43.7%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for TEVA (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.